Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) faces a mixed outlook as Q2 results due in early August — with ~DKK71.5bn revenue and DKK5.04 EPS estimates tied to Wegovy/Zepbound rollouts and CagriSema updates — even as a Phase 3 anti‑inflammatory trial failed and a May buyback boosted trea…
Shares of BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) plunged on Friday after Novo Nordisk’s (NVO) late-stage trial setback raised concerns about biotech stocks pursuing similar approaches to treating heart disease through inflammation reduction.BIOA tumbled 64%, while GLUE dropped about…
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.William Blair analyst Andy Hsieh said the results from Novo Nordisk’s ZEUS trial cast doubt…
Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial.While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive…
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe…
Novo Nordisk A/S (OMXCOP:NOVO_B) sued Eli Lilly over obesity‑drug ads while repurchasing 24.96M B shares into a 0.9% treasury stake, as Wegovy demand surges with Medicare pilots boosting senior access amid debate over competing GLP‑1 vs Lilly’s multi‑target retatrutide.Previous Week Recap…
Plainsboro, NJ and Bagsværd, Denmark, 21 July 2026 – Novo Nordisk Inc. announced today that it has filed a lawsuit against Eli Lilly and Company and Lilly USA, LLC in the United States District Court for the District of New Jersey for multiple violations of federal and state false advertising and u…
SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) HKEX:06086, a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital plat…
Novo Nordisk NYSE:NVO shares rose about 2% on Wednesday after new prescription data indicated its oral weight-loss drug Wegovy continued to lead the U.S. market over Eli Lilly's Foundayo.The report, based on IQVIA data for the week ended July 3, showed the Wegovy pill generated about 153,050 U.S. p…
Eli Lilly (LLY, Financials), the pharmaceutical company behind several diabetes and weight-loss treatments, is off to a slower start than expected with its new obesity pill.U.S. prescription data for the week ended July 3 showed about 19,550 prescriptions for Lilly's Foundayo, compared with roughly…
Danish drugmaker Novo Nordisk (NVO) announced on Wednesday that the European Commission has approved once-daily oral Wegovy for weight management in adults with obesity or overweight and at least one weight-related health condition. The approval makes Wegovy the first oral GLP-1 therapy authorized…
Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) surged ~36% after UK approval of Wegovy amid a Nordic biopharma rebound, while the firm repurchased 22.0M B shares (DKK 5.899bn) in a DKK 11.2bn buyback and struck an India fill–finish deal with Shantha Biologics.Previous Week Recap…
Novo Nordisk NVO has received another commercial boost as the Medicare GLP-1 Bridge program officially went live on July 1, allowing eligible Medicare beneficiaries to access Wegovy (semaglutide injection and pill) for a $50 monthly copay through the end of 2027. The program significantly expands a…
